在近日举行的Angiogenesis 2026大会上，再生元制药公司（Regeneron Pharmaceuticals）重磅公布了其Eylea Hd®（阿柏西普）8毫克注射液的最新临床数据。这些详实的报告进一步巩固了该疗法在应对严重视网膜疾病领域的卓越临床地位。
多项研究结果集中展示，凸显了Eylea Hd®在延长给药间隔、提升患者依从性方面的显著优势，同时其安全性与耐受性特征与已知信息保持一致。这些数据为眼科医生提供了更丰富的治疗选择，尤其对于需要长期管理的慢性视网膜疾病患者而言意义重大。
此次亮相强化了Eylea Hd®作为严重视网膜疾病治疗基石的角色，彰显了再生元在眼科创新疗法研发上的持续投入与领先优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.